Sangamo Therapeutics, Inc (SGMO) — SC 13G/A Filings
All SC 13G/A filings from Sangamo Therapeutics, Inc. Browse 10 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (10)
- SC 13G/A Filing — Nov 12, 2024
- SC 13G/A Filing — Nov 4, 2024
- SC 13G/A Filing — Aug 16, 2024
- SC 13G/A Filing — Jul 8, 2024
- SC 13G/A Filing — Apr 5, 2024
-
Vanguard Adjusts Sangamo Therapeutics Stake to 6.9%
— Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, indicating a change in its ownership of Sangamo Therapeutics Inc. A -
BIOGEN AMENDS SANGAMO STAKE: Ownership Change as of Dec 31, 2023
— Feb 12, 2024 Risk: medium
Biogen Inc. filed an amended Schedule 13G/A on February 12, 2024, indicating a change in its ownership of Sangamo Therapeutics, Inc. common stock as of December -
Wasatch Advisors LP Maintains 7.0% Stake in Sangamo Therapeutics
— Feb 9, 2024 Risk: low
Wasatch Advisors LP, an investment adviser, has updated its ownership stake in Sangamo Therapeutics, Inc. (SGMO) to 7.0% of the common stock, holding 12,397,924 -
BlackRock Amends Sangamo Therapeutics Stake (SC 13G/A)
— Jan 26, 2024
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership of Sangamo Therapeutics Inc. common stock as of December 31, -
State Street Exits Sangamo Therapeutics Stake
— Jan 22, 2024
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating a change in its beneficial ownership of Sanga
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX